An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / email@example.com
IDE397 is an investigational drug, which has not been approved by health authorities for the treatment of people with your medical condition. It is currently not on the market (available for you to receive a prescription for and/or to buy) in any country. The main goals of the study are to determine the safety, tolerability, and effects of IDE397 used as a single agent and in combination with chemotherapy on certain types of cancer. As a single agent, different dose levels of IDE397 will be tested. Different groups of subjects will be treated with increasing dose levels. Every time a dose level is found to be safe, a new dose level will be tested in a new group of subjects until the most appropriate dose is determined. Subjects in the lower dose level may receive IDE397 at the next dose level that is determined to be safe. Once the appropriate dose is determined, further study will aim to determine if this dose is safe and helpful in subjects with certain cancers. Different dose levels of IDE397 will also tested in combination with chemotherapy. Cancers include bladder cancer, breast cancer, colon and rectal cancer, liver cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, and stomach cancer.
Benjamin Herzberg, MD
|Are you at least 18 years old?
|Do you have advanced solid tumors?